The Federal Circuit on Monday affirmed a previous district court dismissal of drug maker AbbVie’s suit against MedImmune Limited over US Patent 6,248,516 (“the ’516 patent”).
The Federal Circuit on Monday affirmed a previous district court dismissal of drug maker AbbVie’s suit against MedImmune Limited over US Patent 6,248,516 (“the ’516 patent”).
AbbVie had, in 2016, sought a declaratory judgment that the ’516 patent, which relates to single-domain ligands derived from molecules in the immunoglobulin superfamily, was invalid. The district court, in granting MedImmune’s motion to dismiss, said that it lacked jurisdiction under the Declaratory Judgment Act, and further said that it would not exercise its jurisdiction if it existed.
AbbVie had entered into a development and licensing agreement, governed under British law, with MedImmune in 1995, stemming from a research collaboration that resulted in adalimumab, which AbbVie today sells as the blockbuster drug Humira. The agreement allowed AbbVie to practice the ’516 patent, among others, for a royalty on the sales of certain antibodies until the last licensed patent expired, or until 15 years after the date of first sale of the product resulting from those antibodies.
The ’516 patent, which will expire on June 19, 2018, is the last of the group of patents to expire (while 15-year royalty period after the first Humira sales ended in January 2018). By seeking to invalidate the ’516 patent, AbbVie sought to truncate the period for which it would be required to pay royalties on Humira. MedImmune argued that, regardless of whether the patent was ruled valid or invalid, AbbVie would still be obligated to pay royalties until the patent’s expiry date, as stipulated in the parties’ contract.
The district court dismissed AbbVie’s complaint, saying that AbbVie does not practice the ’516 patent in producing Humira, so AbbVie is not at risk of infringement and therefore lacks standing to bring an action. It also stated that, even if AbbVie had standing, the 1995 contractual agreement is governed by British contract law, not US law.
In Monday’s ruling, the appellate court said that district court was in error in saying that AbbVie was not at risk of infringement, saying that this interpretation mischaracterized AbbVie’s claim, which concerned contractual obligations.
However, said the court, “AbbVie’s problem is that it did not seek a declaration of its contractual obligations. Rather, AbbVie’s complaint only sought a declaration of invalidity with respect to the ’516 patent.” Because AbbVie has no other pending litigation that would resolve its contractual dispute with MedImmune, the court cannot establish declaratory judgment jurisdiction over the question of the patent’s invalidity.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.